Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Meta-Analysis
. 2006 Oct 18;2006(4):CD006257.
doi: 10.1002/14651858.CD006257.

Angiotensin converting enzyme inhibitors and angiotensin II receptor antagonists for preventing the progression of diabetic kidney disease

G F M Strippoli  1 , C Bonifati, M Craig, S D Navaneethan, J C Craig
Affiliations
Meta-Analysis

Angiotensin converting enzyme inhibitors and angiotensin II receptor antagonists for preventing the progression of diabetic kidney disease

G F M Strippoli et al. Cochrane Database Syst Rev. .

Update in

Abstract

Background: Angiotensin converting enzyme inhibitors (ACEi) and angiotensin II receptor antagonists (AIIRA) are considered to be equally effective for patients with diabetic kidney disease (DKD), but renal and not mortality outcomes have usually been considered.

Objectives: To evaluate the benefits and harms ACEi and AIIRA in patients with DKD.

Search strategy: We searched MEDLINE (1966 to December 2005), EMBASE (1980 to December 2005), the Cochrane Central Register of Controlled Trials (CENTRAL, The Cochrane Library issue 4 2005) and contacted known investigators.

Selection criteria: Studies comparing ACEi or AIIRA with placebo or each other in patients with DKD were included.

Data collection and analysis: Two authors independently assessed trial quality and extracted data. Statistical analyses were performed using the random effects model and results expressed as relative risk (RR) with 95% confidence intervals (CI). Heterogeneity among studies was explored using the Cochran Q statistic and the I(2) test, subgroup analyses and random effects metaregression.

Main results: Fifty studies (13,215 patients) were identified. Thirty eight compared ACEi with placebo, five compared AIIRA with placebo and seven compared ACEi and AIIRA directly. There was no significant difference in the risk of all-cause mortality for ACEi versus placebo (RR 0.91, 95% CI 0.71 to 1.17) and AIIRA versus placebo (RR 0.99, 95% CI 0.85 to 1.17). A subgroup analysis of studies using full-dose ACEi versus studies using half or less than half the maximum tolerable dose of ACEi showed a significant reduction in the risk of all-cause mortality with the use of full-dose ACEi (RR 0.78, 95% CI 0.61 to 0.98). Baseline mortality rates were similar in the ACEi and AIIRA studies. The effects of ACEi and AIIRA on renal outcomes (ESKD, doubling of creatinine, prevention of progression of micro- to macroalbuminuria, remission of micro- to normoalbuminuria) were similarly beneficial. Reliable estimates of effect of ACEi versus AIIRA could not be obtained from the three studies in which they were compared directly because of their small sample size.

Authors' conclusions: Although the survival benefits of ACEi are known for patients with DKD, the relative effects on survival of ACEi with AIIRA are unknown due to the lack of adequate direct comparison studies. In placebo controlled studies, only ACEi (at the maximum tolerable dose, but not lower so-called renal doses) were found to significantly reduce the risk of all-cause mortality. Renal and toxicity profiles of these two classes of agents were not significantly different.

PubMed Disclaimer

Conflict of interest statement

None declared

Figures

1
1
Flow chart showing number of citations retrieved by individual searches, number of trials included in the systematic review and number of trials reporting each outcome.
1.1
1.1
Comparison 1 ACEi versus placebo/no treatment, Outcome 1 All‐cause mortality.
1.2
1.2
Comparison 1 ACEi versus placebo/no treatment, Outcome 2 Cardiovascular mortality.
1.3
1.3
Comparison 1 ACEi versus placebo/no treatment, Outcome 3 Doubling of serum creatinine.
1.4
1.4
Comparison 1 ACEi versus placebo/no treatment, Outcome 4 End‐stage kidney disease.
1.5
1.5
Comparison 1 ACEi versus placebo/no treatment, Outcome 5 Micro‐ to macroalbuminuria.
1.6
1.6
Comparison 1 ACEi versus placebo/no treatment, Outcome 6 Micro‐ to normoalbuminuria.
1.7
1.7
Comparison 1 ACEi versus placebo/no treatment, Outcome 7 Cough.
1.8
1.8
Comparison 1 ACEi versus placebo/no treatment, Outcome 8 Headache.
1.9
1.9
Comparison 1 ACEi versus placebo/no treatment, Outcome 9 Impotence.
1.10
1.10
Comparison 1 ACEi versus placebo/no treatment, Outcome 10 Hyperkalaemia.
2.1
2.1
Comparison 2 AIIRA versus placebo/no treatment, Outcome 1 All‐cause mortality.
2.3
2.3
Comparison 2 AIIRA versus placebo/no treatment, Outcome 3 Doubling of serum creatinine.
2.4
2.4
Comparison 2 AIIRA versus placebo/no treatment, Outcome 4 End‐stage kidney disease.
2.5
2.5
Comparison 2 AIIRA versus placebo/no treatment, Outcome 5 Micro‐ to macroalbuminuria.
2.6
2.6
Comparison 2 AIIRA versus placebo/no treatment, Outcome 6 Micro‐ to normoalbuminuria.
2.7
2.7
Comparison 2 AIIRA versus placebo/no treatment, Outcome 7 Cough.
2.8
2.8
Comparison 2 AIIRA versus placebo/no treatment, Outcome 8 Headache.
2.10
2.10
Comparison 2 AIIRA versus placebo/no treatment, Outcome 10 Hyperkalaemia.
3.1
3.1
Comparison 3 AIIRA versus ACEi, Outcome 1 All‐cause mortality.
3.2
3.2
Comparison 3 AIIRA versus ACEi, Outcome 2 Cardiovascular mortality.
3.5
3.5
Comparison 3 AIIRA versus ACEi, Outcome 5 Micro‐ to macroalbuminuria.
3.6
3.6
Comparison 3 AIIRA versus ACEi, Outcome 6 Micro‐ to normoalbuminuria.
3.7
3.7
Comparison 3 AIIRA versus ACEi, Outcome 7 Cough.
See this image and copyright information in PMC

References

References to studies included in this review

ABCD 1996 {published data only}
    1. Estacio RO, Jeffers B, Biggerstaff S, Schrier RW. Effects of a calcium channel antagonist versus an ace inhibitor on diabetic nephropathy [abstract]. Journal of the American Society of Nephrology 1998;9(Program & Abstracts):114A. [CENTRAL: CN‐00445260]
    1. Estacio RO, Jeffers BW, Gifford N, Schrier RW. Effect of blood pressure control on diabetic microvascular complications in patients with hypertension and type 2 diabetes. Diabetes Care 23;Suppl 2:B54‐64. [MEDLINE: ] - PubMed
    1. Estacio RO, Jeffers BW, Hiatt WR, Biggerstaff SL, Gifford N, Schrier RW. The effect of nisoldipine as compared with enalapril on cardiovascular outcomes in patients with non‐insulin‐dependent diabetes and hypertension. New England Journal of Medicine 1998;338(10):645‐52. [MEDLINE: ] - PubMed
    1. Estacio RO, Mehler P, Esler A, Schrier RW. Aggressive lowering of blood pressure in normotensive type 2 diabetic patients: beneficial effects on stroke, progression of retinopathy and nephropathy [abstract]. Journal of the American Society of Nephrology 2001;12(Program & Abstracts):146A. [CENTRAL: CN‐00445261]
    1. Estacio RO, Savage S, Nagel NJ, Schrier RW. Baseline characteristics of participants in the Appropriate Blood Pressure Control in Diabetes trial. Controlled Clinical Trials 1996;17(3):242‐57. [MEDLINE: ] - PubMed
Ahmad 1997 {published data only}
    1. Ahmad J, Siddiqui MA, Ahmad H. Effective postponement of diabetic nephropathy with enalapril in normotensive type 2 diabetic patients with microalbuminuria. Diabetes Care 1997;20(10):1576‐81. [MEDLINE: ] - PubMed
Ahmad 2003 {published data only}
    1. Ahmad J, Shafique S, Abidi SM, Parwez I. Effect of 5‐year enalapril therapy on progression of microalbuminuria and glomerular structural changes in type 1 diabetic subjects. Diabetes Research & Clinical Practice 2003;60(2):131‐8. [MEDLINE: ] - PubMed
AIPRI 1996 {published data only}
    1. Maschio G, Alberti D, Janin G, Locatelli F, Mann JF, Motolese M, et al. Effect of the angiotensin‐converting‐enzyme inhibitor benazepril on the progression of chronic renal insufficiency. The Angiotensin‐Converting‐Enzyme Inhibition in Progressive Renal Insufficiency Study Group. New England Journal of Medicine 1996;334(15):939‐45. [MEDLINE: ] - PubMed
ATLANTIS SG 2000 {published data only}
    1. O'Hare P, Bilbous R, Mitchell T, O'Callaghan CJ, Viberti GC. Ace‐Inhibitor Trial to Lower Albuminuria in Normotensive Insulin‐Dependent Subjects Study Group. Low‐dose ramipril reduces microalbuminuria in type 1 diabetic patients without hypertension: results of a randomized controlled trial. Diabetes Care 2000;23(12):1823‐9. [MEDLINE: ] - PubMed
Bakris 1994 {published data only}
    1. Bakris GL, Slataper R, Vicknair N, Sadler R. ACE inhibitor mediated reductions in renal size and microalbuminuria in normotensive, diabetic subjects. Journal of Diabetes & its Complications 1994;8(1):2‐6. [MEDLINE: ] - PubMed
Bauer 1992 {published data only}
    1. Bakris GL, Barnhill BW, Sadler R. Treatment of arterial hypertension in diabetic humans: importance of therapeutic selection. Kidney International 1992;41(4):912‐9. [MEDLINE: ] - PubMed
Bojestig 2001 {published data only}
    1. Bojestig M, Karlberg BE, Lindstrom T, Nystrom FH. Reduction of ACE activity is insufficient to decrease microalbuminuria in normotensive patients with type 1 diabetes. Diabetes Care 2001;24(5):919‐24. [MEDLINE: ] - PubMed
Capek 1994 {published data only}
    1. Capek M, Schnack C, Ludvik B, Kautzky‐Willer A, Banyai M, Prager R. Effects of captopril treatment versus placebo on renal function in type 2 diabetic patients with microalbuminuria: a long‐term study. Clinical Investigator 1994;72(12):961‐6. [MEDLINE: ] - PubMed
CAPTOPRIL 1993 {published data only}
    1. Lewis EJ, Hunsicker LG, Bain RP, Rohde RD. The effect of angiotensin‐converting‐enzyme inhibition on diabetic nephropathy. The Collaborative Study Group. New England Journal of Medicine 1993;329(20):1458‐62. [MEDLINE: ] - PubMed
Carella 1999 {published data only}
    1. Carella MJ, Gossain VV, Jones J. The effects of a low‐dose regimen of fosinopril on elevated urinary albumin excretion in normotensive type 1 diabetic patients. Journal of Medicine 1999;30(5‐6):305‐20. [MEDLINE: ] - PubMed
Chase 1993 {published data only}
    1. Chase HP, Garg SK, Harris S, Hoops S, Jackson WE, Holmes DL. Angiotensin‐converting enzyme inhibitor treatment for young normotensive diabetic subjects: a two‐year trial. Annals of Ophthalmology 1993;25(8):284‐9. [MEDLINE: ] - PubMed
Cordonnier 1999 {published data only}
    1. Cordonnier DJ, Pinel N, Barro C, Maynard M, Zaoui P, Halimi S, et al. Expansion of cortical interstitium is limited by converting enzyme inhibition in type 2 diabetic patients with glomerulosclerosis. The Diabiopsies Group. Journal of the American Society of Nephrology 1999;10(6):1253‐63. [MEDLINE: ] - PubMed
Crepaldi 1998 {published data only}
    1. Crepaldi G, Carta Q, Deferrari G, Mangili R, Navalesi R, Santeusanio F, et al. Effects of lisinopril and nifedipine on the progression to overt albuminuria in IDDM patients with incipient nephropathy and normal blood pressure. The Italian Microalbuminuria Study Group in IDDM. Diabetes Care 1998;21(1):104‐10. [MEDLINE: ] - PubMed
DETAIL 2004 {published data only}
    1. Barnett AH, Bain SC, Bouter P, Karlberg B, Madsbad S, Jervell J, et al. Angiotensin‐receptor blockade versus converting‐enzyme inhibition in type 2 diabetes and nephropathy. New England Journal of Medicine 2004;351(19):1952‐61. [MEDLINE: ] - PubMed
DIABHYCAR 2004 {published data only}
    1. Marre M, Lievre M, Chatellier G, Mann J, Passa P, Menard J. Effects of low dose ramipril on cardiovascular and renal outcomes in patients with type 2 diabetes and raised excretion of urinary albumin: randomised, double blind, placebo controlled trial (the DIABHYCAR study). BMJ 2004;328(7438):495‐9. [MEDLINE: ] - PMC - PubMed
ESPRIT 2001 {published data only}
    1. Baines LA. Effect of 3 years of antihypertensive therapy on renal structure in type 1 diabetic patients with albuminuria: the European Study for the Prevention of Renal Disease in Type 1 Diabetes (ESPRIT). Diabetes 2001;50(4):843‐50. [MEDLINE: ] - PubMed
EUCLID 1997 {published data only}
    1. Chaturvedi N, Stevenson J, Fuller JH, Rottiers R, Ferriss B, Karamanos B, et al. Randomised placebo‐controlled trial of lisinopril in normotensive patients with insulin‐dependent diabetes and normoalbuminuria or microalbuminuria. The EUCLID Study Group. Lancet 1997;349(9068):1787‐92. [MEDLINE: ] - PubMed
    1. Penno G, Chaturvedi N, Talmud PJ, Cotroneo P, Manto A, Nannipieri M, et al. Effect of angiotensin‐converting enzyme (ACE) gene polymorphism on progression of renal disease and the influence of ACE inhibition in IDDM patients: findings from the EUCLID Randomized Controlled Trial. EURODIAB Controlled Trial of Lisinopril in IDDM. Diabetes 1998;47(9):1507‐11. [MEDLINE: ] - PubMed
Garg 1998 {published data only}
    1. Garg SK, Chase HP, Jackson WE, Harris S, Carmain JA, Hansen MH, et al. Renal and retinal changes after treatment with Ramipril and pentoxifylline in subjects with IDDM. Annals of Ophthalmology‐Glaucoma 1998;30(1):33‐7. [EMBASE: 1998093196]
Hansen 1994 {published data only}
    1. Hansen KW, Klein F, Christensen PD, Sorensen K, Andersen PH, Moller J, et al. Effects of captopril on ambulatory blood pressure, renal and cardiac function in microalbuminuric type 1 diabetic patients. Diabete et Metabolisme 1994;20(5):485‐93. [MEDLINE: ] - PubMed
    1. Viberti G, Mogensen CE, Groop LC, Pauls JF. Effect of captopril on progression to clinical proteinuria in patients with insulin‐dependent diabetes mellitus and microalbuminuria. European Microalbuminuria Captopril Study Group. JAMA 1994;271(4):275‐9. [MEDLINE: ] - PubMed
HOPE 2000 {published data only}
    1. Gerstein HC, Yusuf S, Mann JF, Hoogwerf B, Zinman B, Held C, et al. Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO‐HOPE substudy. Heart Outcomes Prevention Evaluation Study Investigators. Lancet 2000;355(9200):253‐9. [MEDLINE: ] - PubMed
    1. Mann JF, Gerstein HC, Pogue J, Bosch J, Yusuf S. Renal insufficiency as a predictor of cardiovascular outcomes and the impact of ramipril: the HOPE randomized trial. Annals of Internal Medicine 2001;134(8):629‐36. [MEDLINE: ] - PubMed
IDNT 2001 {published data only}
    1. Berl T, Hunsicker LG, Lewis JB, Pfeffer MA, Porush JG, Rouleau JL, et al. Cardiovascular outcomes in the Irbesartan Diabetic Nephropathy Trial of patients with type 2 diabetes and overt nephropathy. Annals of Internal Medicine 2003;138(7):542‐9. [MEDLINE: ] - PubMed
    1. Lewis EJ, Hunsicker LG, Clarke WR, Berl T, Pohl MA, Lewis JB, et al. Renoprotective effect of the angiotensin‐receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. New England Journal of Medicine 2001;345(12):851‐60. [MEDLINE: ] - PubMed
IRMA‐2 2001 {published data only}
    1. Parving HH, Lehnert H, Brochner‐Mortensen J, Gomis R, Andersen S, Arner P, et al. The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. New England Journal of Medicine 2001;345(12):870‐8. [MEDLINE: ] - PubMed
JAPAN‐IDDM 2002 {published data only}
    1. Katayama S, Kikkawa R, Isogai S, Sasaki N, Matsuura N, Tajima N, et al. Effect of captopril or imidapril on the progression of diabetic nephropathy in Japanese with type 1 diabetes mellitus: a randomized controlled study (JAPAN‐IDDM). Diabetes Research & Clinical Practice 2002;55(2):113‐21. [MEDLINE: ] - PubMed
Jerums 2001 {published data only}
    1. Jerums G, Allen TJ, Campbell DJ, Cooper ME, Gilbert RE, Hammond JJ, et al. Long‐term comparison between perindopril and nifedipine in normotensive patients with type 1 diabetes and microalbuminuria. American Journal of Kidney Diseases 2001;37(5):890‐9. [MEDLINE: ] - PubMed
Jerums 2004 {published data only}
    1. Jerums G, Allen TJ, Campbell DJ, Cooper ME, Gilbert RE, Hammond JJ, et al. Long‐term renoprotection by perindopril or nifedipine in non‐hypertensive patients with type 2 diabetes and microalbuminuria. Diabetic Medicine 2004;21(11):1192‐9. [MEDLINE: ] - PubMed
Ko 2005 {published data only}
    1. Ko GT, Tsang CC, Chan HC. Stabilization and regression of albuminuria in chinese patients with type 2 diabetes: a one‐year randomized study of valsartan versus enalapril. Advances in Therapy 2005;22(2):155‐62. [MEDLINE: ] - PubMed
Lacourciere 2000 {published data only}
    1. Lacourciere Y, Belanger A, Godin C, Halle JP, Ross S, Wright N, et al. Long‐term comparison of losartan and enalapril on kidney function in hypertensive type 2 diabetics with early nephropathy. Kidney International 2000;58(2):762‐9. [MEDLINE: ] - PubMed
Laffel 1995 {published data only}
    1. Laffel LM, McGill JB, Gans DJ. The beneficial effect of angiotensin‐converting enzyme inhibition with captopril on diabetic nephropathy in normotensive IDDM patients with microalbuminuria. North American Microalbuminuria Study Group. American Journal of Medicine 1995;99(5):497‐504. [MEDLINE: ] - PubMed
Lebovitz 1994 {published data only}
    1. Lebovitz HE, Wiegmann TB, Cnaan A, Shahinfar S, Sica DA, Broadstone V, et al. Renal protective effects of enalapril in hypertensive NIDDM: role of baseline albuminuria. Kidney International ‐ Supplement 1994;45:S150‐5. [MEDLINE: ] - PubMed
Marre 1987 {published data only}
    1. Marre M. Microalbuminuria and ACE inhibition in non‐hypertensive diabetics. Journal of Diabetic Complications 1990;4(2):84‐5. [MEDLINE: ] - PubMed
    1. Marre M, Chatellier G, Leblanc H, Guyene TT, Menard J, Passa P. Prevention of diabetic nephropathy with enalapril in normotensive diabetics with microalbuminuria. BMJ 1988;297(6656):1092‐5. [MEDLINE: ] - PMC - PubMed
    1. Marre M, Leblanc H, Suarez L, Guyenne TT, Menard J, Passa P. Converting enzyme inhibition and kidney function in normotensive diabetic patients with persistent microalbuminuria. British Medical Journal Clinical Research Ed 1987;294(6585):1448‐52. [MEDLINE: ] - PMC - PubMed
Mathiesen 1999 {published data only}
    1. Hansen PM, Mathiesen ER, Kofoed‐Enevoldsen A, Deckert T. Possible effect of angiotensin‐converting enzyme inhibition on glomerular charge selectivity. Journal of Diabetes & its Complications 1995;9(3):158‐62. [MEDLINE: ] - PubMed
    1. Mathiesen ER, Hommel E, Giese J, Parving HH. Efficacy of captopril in postponing nephropathy in normotensive insulin dependent diabetic patients with microalbuminuria. BMJ 1991;303(6794):81‐7. [MEDLINE: ] - PMC - PubMed
    1. Mathiesen ER, Hommel E, Hansen HP, Smidt UM, Parving HH. Randomised controlled trial of long term efficacy of captopril on preservation of kidney function in normotensive patients with insulin dependent diabetes and microalbuminuria. BMJ 1999;319(7201):24‐5. [MEDLINE: ] - PMC - PubMed
Muirhead 1999 {published data only}
    1. Muirhead N, Feagan BF, Mahon J, Lewanczuk RZ, Rodger NW, Botteri F, et al. The effects of valsartan and captopril on reducing microalbuminuria in patients with type 2 diabetes mellitus: A placebo‐controlled trial. Current Therapeutic Research, Clinical & Experimental 1999;60(12):650‐60. [EMBASE: 2000024629]
Nankervis 1998 {published data only}
    1. Nankervis A, Nicholls K, Kilmartin G, Allen P, Ratnaike S, Martin FI. Effects of perindopril on renal histomorphometry in diabetic subjects with microalbuminuria: a 3‐year placebo‐controlled biopsy study. Metabolism: Clinical & Experimental 1998;47(12 Suppl 1):12‐5. [MEDLINE: ] - PubMed
O'Donnell 1993 {published data only}
    1. O'Donnell MJ, Rowe BR, Lawson N, Horton A, Gyde OH, Barnett AH. Placebo‐controlled trial of lisinopril in normotensive diabetic patients with incipient nephropathy. Journal of Human Hypertension 1993;7(4):327‐32. [MEDLINE: ] - PubMed
Parving 1989 {published data only}
    1. Parving HH, Hommel E, Damkjaer Nielsen M, Giese J. Effect of captopril on blood pressure and kidney function in normotensive insulin dependent diabetics with nephropathy. BMJ 1989;299(6698):533‐6. [MEDLINE: ] - PMC - PubMed
Parving 2001a {published data only}
    1. Parving HH, Brenner BM, Cooper ME, Zeeuw D, Keane WF, Mitch WE, et al. Effect of losartan on renal and cardiovascular complications of patients with type 2 diabetes and nephropathy. Ugeskrift for Laeger 2001;163(40):5514‐9. [MEDLINE: ] - PubMed
    1. Parving HH, Hommel E, Jensen BR, Hansen HP. Long‐term beneficial effect of ACE inhibition on diabetic nephropathy in normotensive type 1 diabetic patients. Kidney International 2001;60(1):228‐34. [MEDLINE: ] - PubMed
Phillips 1993 {published data only}
    1. Phillips PJ, Phillipou G, Bowen KM, Lowe J, Yue DK, Wischusen J, et al. Diabetic microalbuminuria and cilazapril. American Journal of Medicine 1993;94(4A):58S‐60S. [MEDLINE: ] - PubMed
Poulsen 2001 {published data only}
    1. Poulsen PL, Ebbehoj E, Mogensen CE. Lisinopril reduces albuminuria during exercise in low grade microalbuminuric type 1 diabetic patients: a double blind randomized study. Journal of Internal Medicine 2001;249(5):433‐40. [MEDLINE: ] - PubMed
    1. Poulsen PL, Ebbehoj E, Nosadini R, Fioretto P, Deferrari G, Crepaldi G, et al. Early ACE‐i intervention in microalbuminuric patients with type 1 diabetes: effects on albumin excretion, 24 h ambulatory blood pressure, and renal function. Diabetes & Metabolism 2001;27(2 Pt 1):123‐8. [MEDLINE: ] - PubMed
Ravid 1993 {published data only}
    1. Ravid M, Clutter WE. Long‐term effect of enalapril on normotensive type II diabetes mellitus. Annals of Internal Medicine 1993;119(Suppl 1):6. [EMBASE: 1993289276]
    1. Ravid M, Lang R, Rachmani R, Lishner M. Long‐term renoprotective effect of angiotensin‐converting enzyme inhibition in non‐insulin‐dependent diabetes mellitus. A 7‐year follow‐up study. Archives of Internal Medicine 1996;156(3):286‐9. [MEDLINE: ] - PubMed
    1. Ravid M, Neumann L, Lishner M. Plasma lipids and the progression of nephropathy in diabetes mellitus type II: effect of ACE inhibitors. Kidney International 1995;47(3):907‐10. [MEDLINE: ] - PubMed
    1. Ravid M, Savin H, Jutrin I, Bental T, Katz B, Lishner M. Long‐term stabilizing effect of angiotensin‐converting enzyme inhibition on plasma creatinine and on proteinuria in normotensive type II diabetic patients. Annals of Internal Medicine 1993;118(8):577‐81. [MEDLINE: ] - PubMed
RENAAL 2001 {published data only}
    1. Brenner BM, Cooper ME, Zeeuw D, Keane WF, Mitch WE, Parving HH, et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. New England Journal of Medicine 2001;345(12):861‐9. [MEDLINE: ] - PubMed
Rizzoni 2005 {published data only}
    1. Rizzoni D, Portieri E, Ciuceis C, Sleiman I, Rodella L, Rezzani R, et al. Effect of treatment with candesartan or enalapril on subcutaneous small artery structure in hypertensive patients with noninsulin‐dependent diabetes mellitus. Hypertension 2005;45(4):659‐65. [MEDLINE: ] - PubMed
Romero 1993 {published data only}
    1. Romero R, Salinas I, Lucas A, Abad E, Reverter JL, Johnston S, et al. Renal function changes in microalbuminuric normotensive type II diabetic patients treated with angiotensin‐converting enzyme inhibitors. Diabetes Care 1993;16(4):597‐600. [MEDLINE: ] - PubMed
Sano 1994 {published data only}
    1. Sano T, Hotta N, Kawamura T, Matsumae H, Chaya S, Sasaki H, et al. Effects of long‐term enalapril treatment on persistent microalbuminuria in normotensive type 2 diabetic patients: results of a 4‐year, prospective, randomized study. Diabetic Medicine 1996;13(2):120‐4. [MEDLINE: ] - PubMed
    1. Sano T, Kawamura T, Matsumae H, Sasaki H, Nakayama M, Hara T, et al. Effects of long‐term enalapril treatment on persistent micro‐albuminuria in well‐controlled hypertensive and normotensive NIDDM patients. Diabetes Care 1994;17(5):420‐4. [MEDLINE: ] - PubMed
Sato 2003 {published data only}
    1. Sato A, Tabata M, Hayashi K, Saruta T. Effects of the angiotensin II type 1 receptor antagonist candesartan, compared with angiotensin‐converting enzyme inhibitors, on the urinary excretion of albumin and type IV collagen in patients with diabetic nephropathy. Clinical & Experimental Nephrology 2003;7(3):215‐20. [MEDLINE: ] - PubMed
Stornello 1992 {published data only}
    1. Stornello M, Valvo EV, Scapellato L. Hemodynamic, renal, and humoral effects of the calcium entry blocker nicardipine and converting enzyme inhibitor captopril in hypertensive type II diabetic patients with nephropathy. Journal of Cardiovascular Pharmacology 1989;14(6):851‐5. [MEDLINE: ] - PubMed
    1. Stornello M, Valvo EV, Scapellato L. Persistent albuminuria in normotensive non‐insulin‐dependent (type II) diabetic patients: comparative effects of angiotensin‐converting enzyme inhibitors and beta‐adrenoceptor blockers. Clinical Science 1992;82(1):19‐23. [MEDLINE: ] - PubMed
Tan 2002 {published data only}
    1. Tan KC, Chow WS, Ai VH, Lam KS. Effects of angiotensin II receptor antagonist on endothelial vasomotor function and urinary albumin excretion in type 2 diabetic patients with microalbuminuria. Diabetes/Metabolism Research Reviews 2002;18(1):71‐6. [MEDLINE: ] - PubMed
Trevisan 1995 {published data only}
    1. Trevisan R, Tiengo A. Effect of low‐dose ramipril on microalbuminuria in normotensive or mild hypertensive non‐insulin‐dependent diabetic patients. North‐East Italy Microalbuminuria Study Group. American Journal of Hypertension 1995;8(9):876‐83. [MEDLINE: ] - PubMed
Tutuncu 2001 {published data only}
    1. Tutuncu NB, Gurlek A, Gedik O. Efficacy of ACE inhibitors and ATII receptor blockers in patients with microalbuminuria: a prospective study. Acta Diabetologica 2001;38(4):157‐61. [MEDLINE: ] - PubMed

References to studies awaiting assessment

REIN 1998 {published data only}
    1. Ruggenenti P, Perna A, Gherardi G, Gaspari F, Benini R, Remuzzi G. Renal function and requirement for dialysis in chronic nephropathy patients on long‐term ramipril: REIN follow‐up trial. Gruppo Italiano di Studi Epidemiologici in Nefrologia (GISEN). Ramipril Efficacy in Nephropathy. Lancet 1998;352(9136):1252‐6. [MEDLINE: ] - PubMed

Additional references

ACEIDN 2001
    1. ACE Inhibitors in Diabetic Nephropathy Trialist Group. Should all patients with type 1 diabetes mellitus and microalbuminuria receive angiotensin‐converting‐enzyme inhibitors? A meta‐analysis of individual patient data. Annals of Internal Medicine 2001;134(5):370‐9. [MEDLINE: ] - PubMed
Arauz‐Pacheo 2003
    1. Arauz‐Pacheo C, Parrott MA, Raskin P, American Diabetes Association. Treatment of hypertension in adults with diabetes. Diabetes Care 2003;26 Suppl 1:S80‐2. [MEDLINE: ] - PubMed
Casas 2005
    1. Casas JP, Chua W, Loukogeorgakis S, Vallance P, Smeeth L, Hingorani AD, et al. Effect of inhibitors of the renin‐angiotensin system and other antihypertensive drugs on renal outcomes: systematic review and meta‐analysis. Lancet 2005;366(9502):2026‐33. [MEDLINE: ] - PubMed
Cohn 2001
    1. Cohn JN, Tognoni G, Valsartan Heart Failure Trial Investigators. A randomized trial of the angiotensin‐receptor blocker valsartan in chronic heart failure. New England Journal of Medicine 2001;345(23):1667‐75. [MEDLINE: ] - PubMed
Dinneen 1997
    1. Dinneen SF, Gerstein HC. The association of microalbuminuria and mortality in non‐insulin‐dependent diabetes mellitus. A systematic overview of the literature. Archives of Internal Medicine 1997;157(13):1413‐8. [MEDLINE: ] - PubMed
Garg 1995
    1. Garg R, Yusuf S. Overview of randomized trials of angiotensin‐converting enzyme inhibitors on mortality and morbidity in patients with heart failure. Collaborative Group on ACE Inhibitor Trials. JAMA 1995;273(18):1450‐6. [MEDLINE: ] - PubMed
Grossman 2001
    1. Grossman E, Messerli FH, Goldbourt U. Intensive blood pressure control and drugs reduce morbidity and mortality in hypertension and diabetes mellitus. Evidence Based Medicine 2001;6(2):44. [EMBASE: 2001419226]
Higgins 2003
    1. Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta‐analyses. BMJ 2003;327(7414):557‐60. [MEDLINE: ] - PMC - PubMed
JNC 7 2003
    1. Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo JL Jr, et al. Seventh report of the joint national committee on prevention, detection, evaluation, and treatment of high blood pressure: the JNC‐7 report. JAMA 2003;289(19):2560‐72. [MEDLINE: ] - PubMed
Kasiske 1993
    1. Kasiske BL, Kalil RS, Ma JZ, Liao M, Keane WF. Effect of antihypertensive therapy on the kidney in patients with diabetes: a meta‐regression analysis. Annals of Internal Medicine 1993;118(2):129‐38. [MEDLINE: ] - PubMed
Mogensen 1995
    1. Mogensen CE. Microalbuminuria in prediction and prevention of diabetic nephropathy in insulin‐dependent diabetes mellitus patients. Journal of Diabetes & its Complications 1995;9(4):337‐49. [MEDLINE: ] - PubMed
Mogensen 1999
    1. Mogensen CE. Drug treatment for hypertensive patients in special situations: diabetes and hypertension. Clinical & Experimental Hypertension (New York) 1999;21(5‐6):895‐906. [MEDLINE: ] - PubMed
Ritz 1999
    1. Ritz E, Ortho SR. Nephropathy in patients with type 2 diabetes mellitus. New England Journal of Medicine 1999;341(15):1127‐33. [MEDLINE: ] - PubMed
Strippoli 2005
    1. Strippoli GFM, Craig M, Craig JC. Antihypertensive agents for preventing diabetic kidney disease. Cochrane Database of Systematic Reviews 2005, Issue 4. [DOI: 10.1002/14651858.CD004136.pub2] - DOI - PubMed
Wachtell 2003
    1. Wachtell K, Ibsen H, Olsen MH, Borch‐Johnsen K, Lindholm LH, Mogensen CE, et al. Albuminuria and cardiovascular risk in hypertensive patients with left ventricular hypertrophy: the LIFE study. Annals of Internal Medicine 2003;139(11):901‐6. [MEDLINE: ] - PubMed
Zunetti 1996
    1. Zuanetti G. Prognosis of diabetic patients post‐MI: the role of ACE inhibitor treatment. GISSI‐3 Investigators. Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto Miocardico. Journal of Diabetes & its Complications 1996;10(3):139‐40. [MEDLINE: ] - PubMed

References to other published versions of this review

Strippoli 2004
    1. Strippoli GF, Craig M, Deeks JJ, Schena FP, Craig JC. Effects of angiotensin converting enzyme inhibitors and angiotensin II receptor antagonists on mortality and renal outcomes in diabetic nephropathy: systematic review. BMJ 2004;329(7470):828‐31. [MEDLINE: ] - PMC - PubMed

Publication types

MeSH terms

Substances